All In Biotech

NDA 218754 · Azurity

Aprepitant

Aprepitant · Intravenous

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Jun 16, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

215

62 Phase 3, 9 recruiting

FAERS reports

7,375

7,064 serious, 1,464 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 16, 2026 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
1 products under this application
  • APREPITANT · APREPITANT 130MG/18ML (7.2MG/ML) · EMULSION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aprepitant" as an intervention, any sponsor and status, largest first.

All 215 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue1,287
  • nausea1,105
  • pyrexia921
  • off label use872
  • alopecia823
  • dyspnoea806
  • diarrhoea770
  • rash764
  • vomiting702
  • hypersensitivity701
  • pain690
  • infusion related reaction689

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20047
200515
200628
200724
200829
200948
201066
2011105
2012141
2013169
2014160
2015228
2016393
2017164
2018340
2019413
2020488
2021662
2022634
2023748
20241,025
2025889
2026599

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Aprepitant (Aprepitant)

2024 spending

$8.1M

Beneficiaries

5,483

12,502 claims

Per beneficiary

$1,470

$96.14 per unit

View as table
YearSpending
2020$6,894,884
2021$7,213,060
2022$8,380,869
2023$8,623,535
2024$8,059,237

Part B: Aprepitant* (Aprepitant*) · HCPCS J8501

2024 spending

$1K

Beneficiaries

n/a

12 claims

Per beneficiary

n/a

2024 ASP limit $3.60 per unit

View as table
YearSpending
2020$22,537
2021$12,894
2022$5,403
2023$2,648
2024$1,327

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 324 on PubMed

Sponsor: Azurity

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.